InvestorsHub Logo
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Re: hschlauch post# 35667

Thursday, 08/18/2016 11:02:35 AM

Thursday, August 18, 2016 11:02:35 AM

Post# of 48316
Do you think the registration trial that's been mentioned in their corporate presentation as part of milestones for the next 12 months, could use this biomarker screening being used? I think it could, and imagine if majority of non-responders screened from this are able to respond to Keytruda. That would be epic.
Actually, let's forget majority. If you think about it, Keytruda was approved for melanoma by the FDA for a ~30% response rate. Anything ONCS could add to this rate would be very significant.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News